Filtered By:
Specialty: Pharmaceuticals
This page shows you your search results in order of date.
Order by Relevance | Date
Total 14 results found since Jan 2013.
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
Novartis has acquired DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
DTx’s lead program, DTx-1252 targets the root cause of CMT1A - the overexpression of PMP22, a protein that causes the myelin sheath that supports and insulates nerves in the peripheral nervous system to function abnormally.
Source: World Pharma News - July 19, 2023 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Mitotherapeutix Awarded $2.2 Million SBIR Grant from the National...
siRNA Drug Candidates Suppress Novel NASH Target MCJ(PRWeb June 04, 2021)Read the full story at https://www.prweb.com/releases/mitotherapeutix_awarded_2_2_million_sbir_grant_from_the_national_institutes_of_health_for_sirna_nash_candidates/prweb17984798.htm
Source: PRWeb: Medical Pharmaceuticals - June 4, 2021 Category: Pharmaceuticals Source Type: news
Mitotherapeutix Announces Positive Results from Pre-Clinical Liver...
siRNA Drug Candidates Suppress Novel NASH Target MCJ(PRWeb September 24, 2020)Read the full story at https://www.prweb.com/releases/mitotherapeutix_announces_positive_results_from_pre_clinical_liver_biopsy_study_in_cynomolgus_monkeys/prweb17420856.htm
Source: PRWeb: Medical Pharmaceuticals - September 24, 2020 Category: Pharmaceuticals Source Type: news
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials
VIENNA and GAITHERSBURG, Md., July 8, 2020 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Oncology, Licensing MaxCyte, APEIRON Biologics, cell therapy
Source: HSMN NewsFeed - July 8, 2020 Category: Pharmaceuticals Source Type: news
Oligonucleotide Therapeutics and Delivery Conference 2020
16 - 17 September 2020, London, UK.
Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules.
Source: World Pharma News - April 22, 2020 Category: Pharmaceuticals Tags: Featured Events Source Type: news
Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
GAITHERSBURG, Md., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan Product De... Biopharmaceuticals, Oncology, FDA Sirnaomics, Cholangiocarcinoma
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news
Sirnaomics begins Phase IIa trial of STP705 to treat hypertrophic scar
Biopharmaceutical company Sirnaomics has initiated the Phase IIa trial of its small interfering RNA (siRNA) therapeutic candidate STP705 (Cotsiranib) to treat patients with hypertrophic scar.
Source: Drug Development Technology - February 7, 2017 Category: Pharmaceuticals Source Type: news
Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with Nitto Denko for Targeted siRNA Therapy in Advanced Non-alcoholic Steatohepatitis (NASH) and Cirrhosis Due to NASH
NEW YORK & OSAKA, Japan--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and Nitto Denko Corporation (Nitto) (6988:Tokyo) today announced the companies have entered into an agreement granting Bristol-Myers Squibb exclusive worldw... Biopharmaceuticals, Licensing Bristol-Myers Squibb, Nitto Denko
Source: HSMN NewsFeed - November 10, 2016 Category: Pharmaceuticals Source Type: news
Biocon and Quark begin Phase II/III trial of QPI-1007 for ocular neuroprotection
Indian biopharmaceutical firm Biocon and US-based Quark Pharmaceuticals have announced the initiation of the pivotal global Phase II/III trial (QRK207) of siRNA (small interfering RNA) drug candidate, QPI-1007, for ocular neuroprotection.
Source: Drug Development Technology - June 23, 2016 Category: Pharmaceuticals Source Type: news
GE Healthcare Life Sciences Educational Webinar Presents Getting...
The Webinar on November 13, 2014 will focus on working with siRNA, experimental considerations, and analysis best practices(PRWeb November 11, 2014)Read the full story at http://www.prweb.com/releases/2014/11/prweb12316742.htm
Source: PRWeb: Medical Pharmaceuticals - November 11, 2014 Category: Pharmaceuticals Source Type: news
Merck Dumps Sirna RNAi Assets for $175M
Merck has agreed to sell its Sirna Therapeutics assets to Alnylam Pharmaceuticals, a leading RNAi therapeutics company, for an upfront payment of $175 million in cash and equity.
Source: PharmaManufacturing.com - January 14, 2014 Category: Pharmaceuticals Source Type: news
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference
Dateline City:
WHITEHOUSE STATION, N.J.
Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company’s anti-PD-1 immunotherapy; expects to complete application in first half of 2014.
Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant.
Evaluates the role of Merck’s Animal Health and Consumer Care businesses in the company’s strategy for long-term value creation;...
Source: Merck.com - Corporate News - January 13, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news
Alnylam buys Merck's Sirna Therapeutics
Alnylam Pharmaceuticals has acquired Merck's subsidiary Sirna Therapeutics, comprising intellectual property and RNAi assets, including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies.
Source: Pharmaceutical Technology - January 13, 2014 Category: Pharmaceuticals Source Type: news
Biocon inks licensing pact with US-based Quark Pharma
Biocon today said it has inked a pact with Quark Pharmaceuticals, Inc to develop a range of siRNA (small interfering RNA) based novel therapeutics.
Source: The Economic Times Healthcare and Biotech News - December 18, 2013 Category: Pharmaceuticals Source Type: news
